Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP:CYDY)

0.2500 +0.0059 (+2.42%)
Streaming Delayed Price Updated: 3:58 PM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytodyn Inc

< Previous 1 2 3 4 5 Next >
News headline image
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
News headline image
September 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Settlement with Amarex Clinical Research LLC
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Host Webcast to Provide Company Update
From CytoDyn Inc.
Via GlobeNewswire
News headline image
May 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces FDA Has Lifted Clinical Hold
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Webcast to Provide Company Update
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
From CytoDyn Inc.
Via GlobeNewswire
News headline image
November 2023 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Company Updates and Investment Community Update Webcast
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces President Takes Medical Leave of Absence
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Hold Webcast to Provide a Company Update
From CytoDyn Inc.
Via GlobeNewswire
News headline image
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December ↗
On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate... 
Via Benzinga
News headline image
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
From CytoDyn Inc.
Via GlobeNewswire
News headline image
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes ↗
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. 
Via Benzinga
News headline image
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
From CytoDyn Inc.
Via GlobeNewswire
News headline image
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close ↗
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022. 
Via Benzinga
News headline image
CytoDyn Announces Appointment of Additional Directors with Industry Experience
From CytoDyn Inc.
Via GlobeNewswire
News headline image
OTC Markets' Most Active Securities Sees A Shake-up In July ↗
July gave world markets a breather from 2022’s poor financial conditions. 
Via Benzinga
News headline image
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.